Ten patients with different types of hyperlipoproteiniemia (HLP) were treated with CI-719. The period of drug treatment varied from four to eight weeks.
Changes in triglycerides after four to eight weeks' intake of 800 mg of CI-719 are shown in Table 1 . After four weeks a decrease of triglyceride concentrations was observed in HLP type Ila and Ilb. The response to CI-719 in HLP type IV was different; 3 patients reacted with a marked decrease in serum triglycerides, whereas an increase was seen in 3 other patients. The serum lipids continued to increase in I patient treated for eight weeks with CI-719. The cholesterol level remained elevated in HLP type Ila, and did not change substantially in type lIb. In contrast, lower cholesterol levels were found in 5 patients with HLP type IV, whereas 1 patient reacted with a further increase (Table 1) .
Similar lipoprotein alterations were seen in the composition of lipoprotein fractions of 1 patient each with HLP type hIa and IV. Apart from the different alterations in serum levels, the cholesterol content of the LDL and HDL fractions increased after four weeks of CI-719 administration in both cases. The triglycerides were shifted from the VLDL to the LDL fraction. The phospholipids of HDL were elevated.
Dr J Wilkening
No severe adverse effects were noted. The body weight remained nearly constant during drug taking. A transient rise in creatine phosphokinase was seen in 1 patient. During treatment with CI-719, a trend to reduced fibrinogen levels seemed to have occurred. All other routine laboratory tests remained within the pretreatment values. Transient diarrhcea, heartburn, a circumscribed exanthema and sleepiness were noted occasionally.
In summary, 10 patients were treated with 800 or 1200 mg of CI-719 for four to eight weeks. The substance seems to be effective in lowering triglycerides and possibly cholesterol in type IV and type Ilb hyperlipoproteinemia. Thomas M & Couch R, 1976, Clinical Trials Journal 13, 42) .
Nine patients with hypertriglyceridemia, either type IIb or type IV, were involved. There were two placebo periods, one at the beginning and one at the end. Treatment was continued for four weeks at a dosage of 800 mg/day. Cholesterol and triglyceride responses were similar to those subsequently reported. The fall in cholesterol was 14 % at four weeks, and the fall in triglycerides was of the order of 40 %. However, during the second placebo period there appeared to be a rebound effect both on cholesterol and triglycerides. The Cardiff group were concerned whether this might possibly be associated with an increase in blood coagulation, because one of the patients died abruptly of a myocardial infarct two months after discontinuation of gemfibrozil, although this was most probably a chance occurrence.
In addition, in 1 type V patient, the triglyceride levels were extremely high and showed no response to gemfibrozil. This patient was subsequently treated wvith clofibrate, also with no response, and Dr Greenwood was surprised at some of the responses to gemfibrozil reported in type V patients.
He stressed that patients were singularly free from side effects, although 1 patient did complain of impotence, and this effect had recently been reported in association with clofibrate.
Professor L A Carlson (Chairman) said that these and similar results showed that type V is a very heterogeneous group, at least from the point of view of response to treatment.
Dr H R Arntz (Berlin) asked Dr Wilkening what method he had used for fibrinogen estimations.
He also asked about levels before treatment, because the literature suggested that hyperlipidwmic patients had higher fibrinogen concentrations.
Dr Wilkening said they had used the method of Clauss (Acta Ha?matologica, 1957, 17, 237) to estimate fibrinogen levels. Placebo values were in the normal range, from 2 to 4 g/litre, with a mean baseline value of 2.7 g/litre. The change he referred to was from 2.7 to 2.0 g/litre during the drug phase.
Dr Ghosh asked Dr Janus if he had observed a rebound effect similar to that of Dr Greenwood in the final placebo phase of the study.
Dr Janus said that a few of his patients had completed 26 weeks on the active drug and were about to be changed to placebo, but so far he had no data on this third phase.
Dr Howard said that both Pereira and Hess had claimed that the increase in alpha-glycerophosphate dehydrogenase was responsible for the serum triglyceride lowering with clofibrate. Thus there might be a different mode of action for gemfibrozil.
Dr R E Maxwell (Ann Arbor) said that their own comparative work on alpha-glycerophosphate dehydrogenase in rats had, like that of Dr Howard, led to surprising results.
He had also observed an inhibition of acetyl coA carboxylase by both chlorophenoxyisobutyrate and gemfibrozil and felt that this mechanism could also be involved.
Dr Ylikahri said that, in rats, the hypolipidaemic effect of clofibrate and the effect on mitochondrial alpha-glycerophosphate dehydrogenase had a poor correlation. The hypolipidamic effect occurred with smaller doses than the effect on enzyme activity, and this was also true for changes in the activity of other enzymes. In addition, he felt that gemfibrozil must also have an effect on the particle bound alpha-glycerophosphate dehydrogenase. Dr Maxwell had said that the activities were measured in the total homogenate. Clofibrate had its effect only on the particlebound enzyme. It was known that a considerable portion of this enzyme was in the peroxizomes, which were just microbodies to be increased during gemfibrozil treatment. Thus he believed that this new drug must have an effect on the activity of this enzyme when given in large doses, but it was questionable whether this action was related to the hypolipidaemic effect of the drug.
Professor Carlson asked whether the effect on alpha-glycerophosphate dehydrogenase could be secondary to the hyperlipidtmia, since the effects on lipids preceded the effect on enzyme activity.
Dr Ylikahri doubted this, repeating that in doseresponse studies, the hypolipidwmic effect occurred with smaller doses. In reply to a question from Dr Howard he confirmed that liver enlargement and an increase in the liver/body weight ratio always occurred when such activity was seen.
Dr I McClean Baird (London) said that recent studies showed quite definitely that gallstones were increased three-fold on long-term clofibrate therapy. He asked if Dr Howard thought it important to establish the effect of gemfibrozil on biliary kinetics. Did gemfibrozil affect the cholesterol concentration in bile, and if so was there a diurnal variation?
Dr Howard agreed that this question was most important and that techniques were available to study it. Bile composition could be studied by using duodenal aspirates. It should be possible to obtain an indication whether gemfibrozil was likely to increase gallstone formation.
Professor Nikkila drew attention to discrepancies in the reported effects of gemfibrozil on HDL levels. Results from Glasgow had shown no effect of the drug on the HDL levels. Dr Wilkening, by contrast, had found an increase in the HDL cholesterol and particularly in the HDL phospholipid levels, which was interesting because Dr Bremner reported a decrease in triglycerides in HDL. Earlier in the meeting Dr Vessby had shown a significant increase of HDL cholesterol levels and Professor Nikkila himself had reported a non-significant increase of HDL cholesterol. The effect was not simply a question of dosage, since Dr Wilkening had an effect at 800 mg; Dr Vessby observed an increase with 1200 mg, but Dr Bremner found no increase with 1600 mg/day. So far there was no explanation of the mechanism of increase of HDL, and with reference to recent findings on the importance of low HDL levels in the pathogenesis of atherosclerosis, he thought that even a small increase might be important.
Dr Bremner, in answer to a question from the Chairman, said that on subdividing their group IV patients, those who drank frequently showed no change in total cholesterol or in LDL cholesterol. The group who drank infrequently or not at all showed a drop of some 10% in the total cholesterol owing almost entirely to a fall in VLDL cholesterol.
Dr Howard said that clofibrate had no effect on alcohol-induced hypertriglyceridemia in animals.
Professor Lewis commented on Dr Third's attempts to assess the prevalence of different hyperlipidmmias in the Scottish population by comparing them to normal ranges published in Washington by Fredrickson. He believed her data reflected differences in the frequency of hyperlipidaemia on the two sides of the Atlantic, but it was probably incorrect to regard these as 'prevalences'. There were no special reasons why the US figures should be regarded as standards for the rest of the world.
On the question of gallstones, it was probably certain that the combination of clofibrate and cholestyramine (a common drug combination) might be even more lithogenic than the use of clofibrate alone, because not only was there an increase in biliary cholesterol, but some decrease in the circulating bile acid pool. Dr Howard, however, said that the studies which he had seen reported suggested that cholestyramine treatment did not affect the total bile acid pool, a conclusion with which Professor Nikkila agreed. If this were so, the combination of clofibrate and cholestyramine might also have no effect, but very few data were available.
Dr Bremner had given clofibrate to another group of 17 patients with a type IV abnormality and found an overall drop in total cholesterol of 8 % in these patients. The drop was made up of a fall in both VLDL and LDL cholesterol. Clofibrate was therefore having a similar overall effect on cholesterol as gemfibrozil appeared to in the nondrinking population. This clofibrate group was not screened to exclude the moderate to heavy drinkers.
Professor Carlson returned to the question of lipoprotein lipase. Dr Vessby had reported that gemfibrozil had no effect on lipoprotein lipase activity in adipose tissue. Professor Nikkila had reported a 20% increase in postheparin lipoprotein lipase activity, estimated by his specific immunological method. Dr Bremner had found an increase in lipoprotein lipase, and he was asked to give more details of his methods.
Dr Bremner said that they gave heparin to a fasting patient and took pre-and post-heparin blood samples which were incubated with an artificial substrate, subjected to fatty acid extraction and analysed by gas-liquid chromatography. An increase in lipase activity was found when the patient was on the drug, compared to his non-drug samples. With this simple investigation they measured both hepatic and nonhepatic lipoprotein lipases and made no attempt to differentiate them.
Dr A H Kissebah (London) questioned whether these differences in lipoprotein lipase activity reflected a change in serum triglyceride levels. He had observed that lipoprotein lipase could be regulated by serum triglycerides, and the difference between an increase, no effect or a decrease might be a secondary phenomenon resulting from serum triglyceride changes, rather than a primary effect.
Dr H Lithell (Uppsala) had determined lipoprotein lipase activity with a method which was very specific for the lipase and excluded the activities of monoglyceridases, for example. He reported similar results in patients treated with either gemfibrozil or clofibrate. There was no effect on the lipoprotein lipase activity in adipose tissue. However, when measuring the lipoprotein lipase activity in postheparin plasma, this enzyme activity came from several tissues, and various groups had reported that clofibrate produced an increase in lipase activity in these conditions. Their methods were highly specific for lipoprotein lipase activity and excluded the effects of hepatic lipase. The increase in postheparin plasma must therefore come from some source other than the adipose tissue.
Dr Lithell agreed with the Chairman that the lipase in adipose tissue was found in many locations from the site of synthesis to the site of action, but he felt that this method, which used heparin in high dosage, removed most of the lipoprotein lipase from adipose tissue. Nicotinic acid, on the other hand, increased the lipase in this tissue.
Professor Carlson suggested that it might next be appropriate to measure lipoprotein lipase in skeletal muscle.
Professor Nikkilai thought the suggestion that the increase in lipoprotein lipase in postheparin plasma was related to the decrease in triglycerides might be valid. Even a small increase in the enzyme activity induced by gemfibrozil or clofibrate would account for the rather extensive decrease of triglyceride levels in the circulating plasma. However, there was a poor correlation between the change of LDL activity and the decrease of triglycerides. With clofibrate, he had found an increase of 45 % in enzyme activity compared to only 18 % with gemfibrozil. Nonetheless, the effect on triglycerides was, if anything, greater with gemfibrozil than with clofibrate, despite the fact that Dr Howard had obtained the reverse result. So far, no comparison of these two drugs existed in the same patients, but in different groups of patients in Finland, gemfibrozil seemed a little better than clofibrate in spite of the superior effect of the latter on LDL activity. Further studies were therefore needed, and one should certainly be an investigation of the LDL activity in muscle.
Dr Howard agreed that a cross-over study was necessary. They were performing such a study at a dose level of 1200 mg. It was important to use the same patients and to have equal groups of each.
Professor Schwandt asked whether the lipoprotein lipase in these investigations was in a purified form.
Professor Nikkila had not purified the enzyme because his assay was with a specific antiserum made against the pure hepatic lipase component from human plasma. Attempts which had been made to separate the two lipoprotein lipases, one from adipose tissue and the other from muscle, had so far shown the two enzymes to be identical. The two certainly could not be senarated so far, in postheparin plasma at least.
Dr Ghosh asked Dr Third about the concentration of cholesterol in cord blood samples. Dr Third said that mean values were approximately 60-75 mg/100 ml of blood. She was using a double precipitation method for the lipoprotein, but full statistical analysis of the results had not so far been completed.
Dr Howard asked whether Dr Greenwood's data showed a true rebound phenomenon. Dr Greenwood said that the cholesterol was significantly higher (P<0.5) during the second placebo period compared with the level during gemfibrozil treatment, but the increase in triglycerides was not significant. He felt that his figures did show a true rebound phenomenon rather than a return to the baseline values on administration of placebo.
